Campral is a prescription medication marketed under the brand name Campral that contains acamprosate as its sole active ingredient. It belongs to the therapeutic class of addiction-treatment agents and is specifically approved for the management of alcohol dependence. In Hong Kong, Campral is regulated as a prescription-only product by the Department of Health. The medication is supplied as 333 mg oral pills that are taken by mouth.
Acamprosate’s therapeutic effect stems from its influence on two major neurotransmitter systems that are altered during chronic alcohol use:
The combined effect leads to a smoother transition when a person stops drinking, reducing cravings and the unpleasant sensations that often trigger relapse. Clinical studies have shown that these mechanisms contribute to the maintenance of abstinence rather than to acute withdrawal relief.
Campral is FDA- and EMA-approved (and recognized by Hong Kong regulators) for a single indication:
The medication is not indicated for smoking cessation, cannabis dependence, or other substance-use disorders.
Current peer-reviewed literature provides limited evidence for the use of acamprosate beyond alcohol dependence. Small pilot studies have explored its role in cocaine craving reduction and in cannabis-use disorders, but these investigations have not reached the level of regulatory approval. Because off-label applications lack robust endorsement, any such use requires close medical supervision and a careful risk-benefit assessment.
This article provides educational information about Campral and is not a substitute for professional medical advice. Treatment decisions, including the use of any medication for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Yes, acamprosate tablets may be taken with or without food. Some patients find that a light snack reduces the occasional gastrointestinal upset that can occur with the medication.
If a dose is missed and the next scheduled dose is more than four hours away, take the missed tablet. If it is less than four hours, skip the missed dose and continue with the regular dosing schedule; do not double up.
For individuals with a creatinine clearance between 30 and 50 mL/min, clinicians often reduce the total daily dose (e.g., one tablet three times daily). Severe renal impairment (clearance < 30 mL/min) is an absolute contraindication.
Acamprosate is not a controlled substance and is not typically screened for in standard workplace drug-testing panels. However, laboratory policies vary, so it is advisable to inform the testing facility if concerns arise.
All three drugs support alcohol-dependence treatment, but they act via different mechanisms: Campral modulates glutamate and GABA pathways, disulfiram produces an aversive reaction when alcohol is consumed, and naltrexone blocks opioid receptors that mediate alcohol reward. Choice of therapy depends on individual health status and treatment goals.
Yes, but keep the medication in its original labeled container, carry a copy of the prescription, and be prepared to declare it at customs if required. In Hong Kong, you must have a valid prescription to possess Campral.
Acamprosate has a low potential for herb-drug interactions, but it is prudent to disclose all supplements (e.g., St. John’s wort, valerian) to your prescriber, as some herbs can influence central nervous system activity.
Clinical guidelines recommend maintaining acamprosate for at least six months to support continued abstinence. The exact duration should be individualized based on relapse risk and ongoing counseling support.
Campral tablets are circular, white, and imprinted with the dosage strength “333 mg.” The tablets are film-coated to aid swallowing.
Campral is specifically approved for alcohol dependence and has no established efficacy for nicotine addiction. Patients seeking smoking cessation should discuss FDA-approved options such as nicotine-replacement therapy or varenicline with their healthcare provider.
